Advanced search
Publication Cover
Infectious Diseases Volume 50, 2018 - Issue 4
Submit an article Journal homepage
45
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Successful treatment of HIV-/HCV-coinfected patients in the era of direct acting antivirals: is advanced liver disease still a limiting factor?

Jose Armando Gonzales ZamoraDivision of Infectious Diseases, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USACorrespondence[email protected]
Pages 320-323 | Received 19 Sep 2017, Accepted 25 Oct 2017, Published online: 12 Nov 2017

References

  • HCV guidance. Recommendations for testing, managing and treating hepatitis C. Infections Disease Society of America (IDSA) and American Association for the Study of Liver Diseases (AASLD). 2016. Available from: http://hcvguidelines.org/
  • Lagging M, Wejstål R, Norkrans G, et al. Treatment of hepatitis C virus infection: updated Swedish guidelines 2016. Infect Dis (Lond). 2017;49:561–575.
  • Lacombe K, Fontaine H, Dhiver C, et al. Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV Coinfected patients with advanced liver disease in a French early access cohort. J Acquir Immune Defic Syndr. 2017;75:97–107.
  • Mandorfer M, Schwabl P, Steiner S, et al. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. AIDS. 2016;30:1039–1047.
  • Lakshmi S, Alcaide M, Palacio AM, Shaikhomer M, Alexander AL, Gill-Wiehl G, Pandey A, Patel K, Jayaweera D, Del Pilar Hernandez M. Improving HCV cure rates in HIV-coinfected patients – a real-world perspective. Am J Manag Care. 2016;22:SP198–SP204.
  • Menard A, Colson P, Catherine D, et al. First real life evidence of new Direct-acting Antivirals (DAA) in co-infected HIV HCV patients: better than ever. Clin Infect Dis. 2016;62:947–949.
  • Hawkins C, Grant J, Ammerman LR, et al. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective. J Antimicrob Chemother. 2016;71:2642–2645.
  • Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV Aids. 2011;6:478–482.
  • McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis. 2007;44:431–437.
  • Bongiovanni M, Gori A, Lepri AC, Italian Cohort of Antiretroviral-Naive Patients Study Group, et al. Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis? Clin Infect Dis. 2007;45:650–653.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.